Previous 10 | Next 10 |
home / stock / addxf / addxf news
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO a...
Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule discovery technology platform to Neurosterix Ad Hoc Announcem...
Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking pl...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the company has entered into an...
Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Sw...
CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 20, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”)...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 14, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”)...
ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024 mGlu2 NAM cognition program receives a €4 million Eurostars grant CHF 4.8M ($5.2M) of cash and cash equivalents at September 30, 2023 Ad Hoc A...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that an Extraor...
News, Short Squeeze, Breakout and More Instantly...
Addex Pharms Ltd Ord Company Name:
ADDXF Stock Symbol:
OTCMKTS Market:
Addex Pharms Ltd Ord Website:
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024 . Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutic...